Medicare Procedure and Patient Information
2020 Medicare Patient Data
Information about Medicare patients treated by Dr. Willis Harck Navarro, MD.
| Non-Hispanic White | |
|---|---|
| Black | |
| Hispanic | |
| Asian | |
| Other | |
| Native American |
(No ratings)
Dr. Willis Harck Navarro, MD is a medical oncologist in Tucson, AZ specializing in medical oncology, physician and hematology (blood disorders). Dr. Willis Harck Navarro, MD is affiliated with The University of Arizona Cancer Center and University of Arizona Cancer Center.
Information about Medicare patients treated by Dr. Willis Harck Navarro, MD.
| Non-Hispanic White | 11 |
|---|---|
| Black | 0 |
| Hispanic | 0 |
| Asian | 0 |
| Other | 0 |
| Native American | 0 |
| Hypertension | 75 |
|---|---|
| High Cholesterol | 61 |
| Stroke | 0 |
| Ischemic Heart Disease | 61 |
| Depression | 0 |
| Chronic Kidney Disease | 72 |
| Asthma | 0 |
| Osteoperosis | 0 |
| Atrial Fibrilation | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Dementia | 0 |
| Cancer | 0 |
Volume of procedures performed by Dr. Willis Harck Navarro, MD for Medicare patients.
| doctor visit | 16 |
|---|
| Hypertension | 75 |
|---|---|
| High Cholesterol | 75 |
| Stroke | 0 |
| Ischemic Heart Disease | 0 |
| Depression | 0 |
| Chronic Kidney Disease | 0 |
| Asthma | 0 |
| Osteoperosis | 0 |
| Atrial Fibrilation | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Dementia | 0 |
| Cancer | 0 |
| Hypertension | 75 |
|---|---|
| High Cholesterol | 75 |
| Stroke | 0 |
| Ischemic Heart Disease | 0 |
| Depression | 0 |
| Chronic Kidney Disease | 0 |
| Asthma | 0 |
| Osteoperosis | 0 |
| Atrial Fibrilation | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Dementia | 0 |
| Cancer | 0 |
Volume of procedures performed by Dr. Willis Harck Navarro, MD for Medicare patients.
| doctor visit | 16 |
|---|
Information about Medicare patients treated by Dr. Willis Harck Navarro, MD.
| Black / African American | 0 |
|---|---|
| Asian / Pacific Islander | 0 |
| Non-Hispanic White | 2 |
| Hispanic | 0 |
| Native American / Alaskan Native | 0 |
| Other | 0 |
The highest averages of the most common conditions of Medicare patients that Dr. Willis Harck Navarro, MD treated were hypertension, high cholesterol, chronic kidney disease and ischemic heart disease.
| Hypertension | 56 |
|---|---|
| High Cholesterol | 52 |
| Stroke | 0 |
| Ischemic Heart Disease | 15 |
| Depression | 0 |
| Chronic Kidney Disease | 18 |
| Asthma | 0 |
| Osteoporosis | 0 |
| Heart Failure | 0 |
| Chronic Obstructive Pulmonary Disease | 0 |
| Diabetes | 0 |
| Atrial Fibrillation | 0 |
| Cancer | 0 |
| Dementia | 0 |
He completed residency at Yale New Haven Medical Center. He has a state license in Arizona.
Residency: Yale New Haven Medical Center (1993)
Licensed In: Arizona
Dr. Willis Harck Navarro, MD does not have any reviews yet, be the first to leave a review of Dr. Willis Harck Navarro, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Willis Harck Navarro, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| Pfizer Inc. |
$266
$266 |
|
|---|---|---|
| Incyte Corporation |
$203
MONJUVI $110 |
$93 |
| Amgen Inc. |
$143
$143 |
|
| Celgene Corporation |
$118
$118 |
|
| Merck Sharp & Dohme Corporation |
$42
KEYTRUDA $42 |
|
| Other |
$27
Venclexta $27 |
| Food and Beverage | $440 |
|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $266 |
| Education | $93 |
Patient-based: -Patient involvement, education, and empowerment -Respect for diversity, differences in experiences, and viewpoints -Mutual goal setting and decision-making Teams-based Knowledge-based -Maintaining state-of-art standards of treatment and care through ongoing acquisition of the latest information about hematologic cancers -Participation in clinical trials when appropriate